Imeglimin Induces Reversible Changes in γ-Glutamyl Transferase Associated with Total Cholesterol: A Post-Hoc Analysis of the INFINITY Study
Preprint
- 1 July 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background: Imeglimin is a novel oral antidiabetic agent that improves mitochondrial function and glucose metabolism in patients with type 2 diabetes mellitus (T2DM). Its effects on liver enzymes remain unclear. We investigated the effects of imeglimin on hepatic biomarkers, particularly γ-glutamyl transpeptidase (γ-GTP), and the reversibility of these changes after treatment discontinuation. Methods: This post-hoc analysis of the prospective INFINITY Study included 25 patients with T2DM who completed 6 months of imeglimin treatment followed by a 3-month withdrawal period. Clinical parameters were averaged within predefined 3-month study phases. Treatment responses and withdrawal rebounds were analyzed. Results: Imeglimin significantly improved glycemic control. The geometric mean γ-GTP decreased from 36.2 (27.1–48.4) U/L during the Baseline Phase to 31.1 (23.5–41.1) U/L during the Late Treatment Phase (P < 0.05). Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) also showed downward trends, although these changes were not statistically significant. During the Withdrawal Phase, γ-GTP returned to 35.6 (26.4–48.5) U/L (P < 0.05 vs. Late Treatment Phase). Patients with baseline γ-GTP >50 U/L showed larger but non-significant changes. Treatment response and withdrawal rebound were inversely correlated (r = −0.480, P = 0.015). Only total cholesterol correlated with γ-GTP during both treatment (r = 0.554, P = 0.005) and withdrawal (r = 0.450, P = 0.024). Conclusions: Imeglimin selectively reduced γ-GTP in patients with T2DM, and this effect was reversible after treatment discontinuation. The close association between γ-GTP and total cholesterol suggests that imeglimin may influence hepatic metabolism beyond glucose lowering.Keywords
All Related Versions
This publication has 16 references indexed in Scilit:
- Cost‐Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in the United StatesDiabetes, Obesity and Metabolism, 2026
- Close multilevel links between metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitusMetabolism Open, 2025
- Efficacy and safety of imeglimin, a novel oral agent in the management of type 2 diabetes mellitus: a systematic review and meta-analysisNaunyn-Schmiedeberg's Archives of Pharmacology, 2025
- Exploring new mechanisms of Imeglimin in diabetes treatment: Amelioration of mitochondrial dysfunctionBiomedicine & Pharmacotherapy, 2024
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementJournal of Hepatology, 2020
- Mechanisms of NAFLD development and therapeutic strategiesNature Medicine, 2018
- Circulating gamma glutamyltransferase and prediction of cardiovascular diseaseAtherosclerosis, 2015
- Glutathione synthesisBiochimica et Biophysica Acta (BBA) - General Subjects, 2013
- Elevated Serum GGT Concentrations Predict Reduced Insulin Sensitivity and Increased Intrahepatic LipidsHormone and Metabolic Research, 2005
- Gamma Glutamyl TransferaseCritical Reviews in Clinical Laboratory Sciences, 2001